# Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Canonical URL: https://biopharmsignal.com/news/NBTX/nanobiotix-announces-pricing-of-oversubscribed-85m-global-offering-0a62d5e9
Ticker: NBTX
Company: Nanobiotix
Source: Nanobiotix
Published: 2026-05-21 14:57 EST
## Summary

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the pricing of its previously announced global follow-on offering, consisting of (i) a public offering of 225,373 American Depositary Shares (“ ADSs ”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “ Ordinary Share ”), of the Company, in the United States (the “ U.S. Offering ”) at an offering price of $38.98 per ADS, and (ii) an offering of (a) 1,959,289 Ordinary Shares and (b) 345,099 pre-funded warrants to subscribe for one Ordinary Share each (the “ PFW ”), exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “ Prospectus Regulation ”), and certain other countries (excluding the United States and Canada) (the “ International Offering ”, together with the U.S. Offering, the “ Global Offering ”), at an offering price of €33.60 per Ordinary Share and €33.57 per PFW.

## Article Body
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the pricing of its previously announced global follow-on offering, consisting of (i) a public offering of 225,373 American Depositary Shares (“ ADSs ”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “ Ordinary Share ”), of the Company, in the United States (the “ U.S. Offering ”) at an offering price of $38.98 per ADS, and (ii) an offering of (a) 1,959,289 Ordinary Shares and (b) 345,099 pre-funded warrants to subscribe for one Ordinary Share each (the “ PFW ”), exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “ Prospectus Regulation ”), and certain other countries (excluding the United States and Canada) (the “ International Offering ”, together with the U.S. Offering, the “ Global Offering ”), at an offering price of €33.60 per Ordinary Share and €33.57 per PFW.
## Recent Company News
- 2026-06-05 20:15 EST — [Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social](https://biopharmsignal.com/news/NBTX/information-mensuelle-relative-au-nombre-total-de-droits-de-vote-et-d-actions-co-7ae99676) — Source: Nanobiotix
- 2026-06-05 20:15 EST — [Voting Rights and Shares Capital of the Company](https://biopharmsignal.com/news/NBTX/voting-rights-and-shares-capital-of-the-company-e4d12ebe) — Source: Nanobiotix
- 2026-06-02 20:30 EST — [Nanobiotix fait le point sur sa tresorerie et son activite operationnelle pour le premier trimestre 2026](https://biopharmsignal.com/news/NBTX/nanobiotix-fait-le-point-sur-sa-tresorerie-et-son-activite-operationnelle-pour-l-bd477f84) — Source: Nanobiotix
- 2026-06-02 20:30 EST — [Nanobiotix Provides First Quarter 2026 Operational and Financial Update](https://biopharmsignal.com/news/NBTX/nanobiotix-provides-first-quarter-2026-operational-and-financial-update-9771bec3) — Source: Nanobiotix
- 2026-06-02 06:30 EST — [Nanobiotix rejoint l'indice Euronext Tech Leaders](https://biopharmsignal.com/news/NBTX/nanobiotix-rejoint-l-indice-euronext-tech-leaders-a0f42fda) — Source: Nanobiotix
## Related News
- 2026-07-29 10:30 EST — BSX — [Boston Scientific announces results for second quarter 2026](https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2026-cbac35ee)
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)